Mostrando 5 resultados de: 5
Filtros aplicados
Área temáticas
Medicina forense; incidencia de enfermedades(5)
Medicina y salud(2)
Microorganismos, hongos y algas(2)
Bioquímica(1)
Origen
scopus(5)
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
ArticleAbstract: The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health EnglaPalabras claves:Autores:Aanensen D.M., Abudahab K., Adams H., Afifi S., Amato R., Ariani C.V., Ash A., Barrett J.C., Batra R., Beckett A.H., Beer R., Bernardo M. Gutierrez, Berry L., Bird P.W., Bonsall D., Boswell T., Boyd O., Bresner C., Campbell S., Chand M., Charalampous T., Clark G., Cogger B.J., Connor T.R., Cortes N., Curran T., Dabrera G., Edgeworth J., Fairley D.J., Fallon K., Fleming V.M., Fraser C., Fuller W., Gaythorpe K., Geidelberg L., Golubchik T., Goncalves S., Groves N., Guest M., Gulliver H., Harrison I., Hassan-Ibrahim M.O., Helmer T., Hill V., Hinsley W.R., Holmes C., Howson-Wells H.C., Jackson B., Jackson D.K., John M., Johnson R., Jones C., Jorgensen D., Joseph A., Khakh M., Kidd S., Kitchen C., Koshy C., Kwiatkowski D.P., Laydon D.J., Lister M.M., Loman N.J., Lynch J., Maksimovic J., Malone C.S., Marchbank A., McCluggage K., McCrone J.T., McKenna J.P., Menegazzo M., Merrick I., Mishra S., Moore N., Morgan S., Mori M., Munn R., Myers R., Nebbia G., O’toole A., Patel A., Price A., Ragonnet-Cronin M., Raviprakash V., Reynolds N., Robson S.C., Sheriff N., Sillitoe J., Smith W., Snell L.B., Southgate J., Spellman K., Tang J., Taylor B.E.W., Underwood A.P., Volz E.M., Wantoch M., Warne B., Willingham I., Wise E.L., Workman T., Yeats C.A.Fuentes:scopusCOVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study
ArticleAbstract: The Delta (B.1.617.2) variant was the predominant UK circulating SARS-CoV-2 strain between May and DPalabras claves:Autores:Aanensen D.M., Abudahab K., Adams A., Adams H., Afifi S., Aggarwal D., Ahmad S.S.Y., Aigrain L., Alcolea-Medina A., Alikhan N.F., Allara E., Amato R., Angyal A., Annett T., Antonelli M., Aplin S., Ariani C.V., Asad H., Ash A., Ashfield P., Ashford F., Atkinson L., Attwood S.W., Auckland C., Aydin A., Baker D.J., Baker P., Balcazar C.E., Ball J., Barrett J.C., Barrow M., Barton E., Bashton M., Bassett A.R., Batra R., Baxter C., Bayzid N., Beaver C., Beckett A.H., Beckwith S.M., Bedford L., Beer R., Beggs A., Bellis K.L., Bernardo M. Gutierrez, Berry L., Bertolusso B., Best A., Betteridge E., Bibby D., Bicknell K., Binns D., Birchley A., Bird P.W., Bishop C., Blacow R., Blakey V., Blane B., Bolt F., Bonfield J., Bonner S., Bonsall D., Boswell T., Bosworth A., Bourgeois Y., Boyd O., Bradley D.T., Breen C., Bresner C., Breuer J., Bridgett S., Bronner I.F., Brooks E., Broos A., Brown J.R., Bucca G., Buchan S.L., Buck D., Bull M., Burns P.J., Burton-Fanning S., Byaruhanga T., Byott M., Campbell S., Canas L.S., Capdevila J., Carabelli A.M., Cargill J.S., Carlile M., Carvalho S.F., Chen L., Deng J., Fox B., Graham M.S., Kerfoot E., Kläser K., May A., Molteni E., Murray B., Österdahl M.F., Wolf J.Fuentes:scopusHospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
ArticleAbstract: Background: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. IPalabras claves:Autores:Aanensen D.M., Abudahab K., Adams H., Afifi S., Aliabadi S., Ash A., Batra R., Beckett A.H., Beer R., Bernardo M. Gutierrez, Berry L., Betancor G., Bird P.W., Blakey V., Bonsall D., Boswell T., Bresner C., Campbell S., Carlile M., Charalampous T., Charlett A., Clark G., Cogger B.J., Coll F., Connor T.R., Cortes N., Curran T., Dabrera G., De Angelis D., Debebe J., Edgeworth J., Fairley D.J., Fallon K., Fleming V.M., Fraser C., Fuller W., Gallagher E., Golubchik T., Guest M., Gulliver H., Harris R.J., Hassan-Ibrahim M.O., Helmer T., Holmes C., Holmes N., Hope R., Howson-Wells H.C., John M., Jones C., Joseph A., Khakh M., Kidd S., Kitchen C., Koshy C., Lister M.M., Loose M.W., Lopez-Bernal J., Lynch J., Maksimovic J., Malone C.S., Marchbank A., McCluggage K., McKenna J.P., Menegazzo M., Merrick I., Moore C., Moore N., Morgan S., Mori M., Munn R., Nebbia G., Nyberg T., Patel A., Presanis A.M., Price A., Raviprakash V., Reynolds N., Robson S.C., Sang F., Seaman S.R., Sheriff N., Signell A.W., Sinnathamby M.A., Smith W., Snell L.B., Southgate J., Spellman K., Tang J., Taylor B.E.W., Thelwall S., Twohig K.A., Underwood A.P., Wantoch M., Warne B., Williams L.A., Willingham I., Wise E.L., Workman T., Wright V., Yeats C.A., Zaidi A.Fuentes:scopusSARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
ArticleAbstract: Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response toPalabras claves:Autores:Abraham P., Adams H., Adele S., Afifi S., Asamaphan P., Ash A., Ashraf S., Austin J.A., Azim Ansari M., Barnes E., Barrow M., Beckwith S.M., Beer R., Bernardo M. Gutierrez, Bonsall D., Bresner C., Brown A., Buchan S.L., Cantoni D., Connor T.R., Cowton V., Curran T., Cutino-Moguel T., da Silva Filipe A., Davis C., De Lorenzo G., de Silva T.I., Deeks A.S., Dunachie S.J., Duncan C.J.A., Edgeworth J., Fairley D.J., Fraser C., Fryer H., Fuller W., Furnon W., Golubchik T., Grove J., Guest M., Gunson R., Harvey W.T., Holden M.T.G., Holland P., Hughes J., John M., Jones O., Kele B., Kitchen C., Klenerman P., Koshy C., Kronsteiner B., Logan N., Lythgoe K., Mack A., MacLean O.A., Maksimovic J., Manali M., Mantzouratou A., Marchbank A., McCluggage K., McKenna J.P., Merrick I., Moore S.C., Morgan S., Morriss A., Munn R., Murcia P.R., Murray A., Murray S.M., Nebbia G., Orton R.J., Pascall D.J., Patel A., Patel A.H., Patel B., Payne R.P., Pinto R.M., Price A., Puxty K., Reynolds N., Richter A., Scott S., Shaaban S., Silva V., Singleton D., Smollett K., Southgate J., Spellman K., Szemiel A., Templeton K.E., Thomson L., Tong L., Turtle L., Vink E., Warne B., Whalley T., Wilkie C., Willett B.J., Workman T., Yebra G.Fuentes:scopusPublisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (Nature Microbiology, (2022), 7, 8, (1161-1179), 10.1038/s41564-022-01143-7)
OtherAbstract: In the version of this article initially published, the author affiliation information was incompletPalabras claves:Autores:Abraham P., Adams H., Adele S., Afifi S., Asamaphan P., Ash A., Ashraf S., Austin J.A., Azim Ansari M., Barnes E., Barrow M., Beckwith S.M., Beer R., Bernardo M. Gutierrez, Bonsall D., Bresner C., Brown A., Buchan S.L., Cantoni D., Connor T.R., Cowton V., Curran T., Cutino-Moguel T., da Silva Filipe A., Davis C., De Lorenzo G., de Silva T., Deeks A.S., Dunachie S., Dunachie S.J., Duncan C.J.A., Fairley D.J., Fraser C., Fryer H., Fuller W., Furnon W., Golubchik T., Grove J., Guest M., Gunson R.N., Harvey W.T., Holden M.T.G., Holland P., Hughes J., John M., Jones O., Kele B., Kitchen C., Klenerman P., Koshy C., Kronsteiner B., Logan N., Lythgoe K., Mack A., MacLean O.A., Maksimovic J., Manali M., Mantzouratou A., Marchbank A., McCluggage K., McKenna J.P., Merrick I., Moore S.C., Morgan S., Morriss A., Munn R., Murcia P.R., Murray A., Murray S.M., Nebbia G., Orton R.J., Pascall D.J., Patel A., Patel A.H., Patel B., Payne R.P., Pinto R.M., Price A., Puxty K., Reynolds N., Richter A., Scott S., Shaaban S., Silva V., Singleton D., Smollett K., Southgate J., Spellman K., Szemiel A., Templeton K., Thomson L., Tong L., Turtle L., Vink E., Warne B., Whalley T., Wilkie C., Willett B.J., Workman T., Yebra G.Fuentes:scopus